Arbutus Biopharma Corporation

(NASDAQ:ABUS)

Latest On Arbutus Biopharma Corporation (ABUS):

Date/Time Type Description Signal Details
2023-05-18 02:45 ESTNewsArbutus: Two Data Readouts Of AB-729 Could Shift Momentum In 2023N/A
2023-05-04 21:46 ESTNewsArbutus Biopharma Corporation (ABUS) Q1 2023 Earnings Call TranscriptN/A
2023-05-04 08:45 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67MN/A
2023-04-25 14:16 ESTNewsArbutus sheds 18% after FDA clinical hold on antiviralN/A
2023-04-12 00:01 ESTNewsModerna wins appeals court ruling in Arbutus COVID vaccine patent disputeN/A
2023-04-05 02:46 ESTNewsPfizer, BioNTech dip as Arbutus charges violation of COVID vaccine patentsN/A
2023-03-02 12:31 ESTNewsArbutus Biopharma GAAP EPS of -$0.46 misses by $0.33, revenue of $39M beats by $32.88MN/A
2023-03-02 12:30 ESTNewsArbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 22:16 ESTNewsArbutus Biopharma FY 2022 Earnings PreviewN/A
2023-02-23 11:16 ESTNewsArbutus Biopharma Corp.: Long Road Ahead For HBV CureN/A
2022-11-09 19:33 ESTNewsArbutus Biopharma GAAP EPS of -$0.12 beats by $0.01, revenue of $5.95M misses by $3.23MN/A
2022-11-09 19:32 ESTNewsArbutus Biopharma Corporation (ABUS) Q3 2022 Earnings Call TranscriptN/A
2022-11-09 19:32 ESTNewsArbutus trades higher as Q3 net loss narrows, revenue grows on license dealN/A
2022-11-07 14:15 ESTNewsArbutus Biopharma (ABUS) presents at AASLD 2022 - SlideshowN/A
2022-11-03 05:01 ESTNewsArbutus gains after court denies Moderna motion to dismiss Covid-19 royalties caseN/A
2022-09-12 13:02 ESTNewsArbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'N/A
2022-08-30 16:31 ESTNewsArbutus stock rises on US patent linked to hepatitis B therapy AB-729N/A
2022-08-04 22:47 ESTNewsArbutus Biopharma GAAP EPS of -$0.10 beats by $0.03, revenue of $14.24M beats by $7.47MN/A
2022-08-04 22:46 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 16:46 ESTNewsArbutus Biopharma Q2 2022 Earnings PreviewN/A
2022-07-20 18:00 ESTNewsArbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trialN/A
2022-06-30 05:46 ESTNewsArbutus: 2 Key Catalysts To Look Forward To After EASL Data ReleaseN/A
2022-06-06 15:46 ESTNewsArbutus and Vaccitech begin trial testing combo therapy for chronic hepatitis B virus treatmentN/A
2022-05-05 20:18 ESTNewsArbutus Biopharma GAAP EPS of -$0.11 beats by $0.05, revenue of $12.58M beats by $8.16MN/A
2022-05-05 20:16 ESTNewsArbutus Biopharma Corp (ABUS) CEO William Collier on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 21:31 ESTNewsArbutus Biopharma Q1 2022 Earnings PreviewN/A
2022-03-19 19:34 ESTNewsArbutus sued to avoid patent dispute over Pfizer/BioNTech COVID-19 shotN/A
2022-03-14 23:02 ESTNewsArbutus price target raised at H.C. Wainwright on upcoming data readoutsN/A
2022-03-08 08:32 ESTNewsArbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of InterestN/A
2022-03-04 00:32 ESTNewsArbutus Biopharma GAAP EPS of -$0.83 beats by $0.03, revenue of $11M beats by $0.35MN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-04 00:31 ESTNewsArbutus Biopharma Corporation (ABUS) CEO William Collier on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-02 12:45 ESTNewsArbutus Biopharma Q4 2021 Earnings PreviewN/A
2022-03-01 02:17 ESTNewsModerna hit by lawsuit as Arbutus, Genevant seek damages for use of COVID-19 vaccine patentsN/A
2022-01-24 16:17 ESTNewsArbutus Biopharma outlines milestones for 2022N/A
2021-12-22 11:31 ESTNewsRoivant Sciences Nearly Doubles Since Moderna Patent Ruling, Buy ArbutusN/A
2021-12-17 17:31 ESTNewsArbutus Biopharma: How Will Patent Win Impact Stock Outlook?N/A
2021-12-13 14:32 ESTNewsArbutus in up to $300M deal with Qilu in China for hepatitis B candidate; shares up 7%N/A
2021-12-08 01:33 ESTNewsArbutus identifies molecular targets for COVID-19 treatmentN/A
2021-12-01 16:46 ESTNewsModerna loses patent fight against Arbutus related to vaccines; Arbutus up 40%N/A
2021-12-01 16:46 ESTNewsArbutus chronic hepatitis B virus treatment shows antiviral activity in early-stage trialN/A
2021-12-01 16:46 ESTNewsRoivant Sciences benefits from Arbutus patent win over Moderna; shares up 37%N/A
2021-11-20 03:16 ESTNewsArbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive InvestmentN/A
2021-11-19 06:32 ESTNewsAlnylam, Arrowhead gain on Novo bid to acquire DicernaN/A
2021-11-05 00:18 ESTNewsArbutus Biopharma EPS in-line, beats on revenueN/A
2021-11-05 00:16 ESTNewsArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-04 03:02 ESTNewsArbutus Biopharma Q3 2021 Earnings PreviewN/A
2021-10-09 16:30 ESTNewsA look at the biopharmas developing new treatments for liver diseasesN/A
2021-10-07 03:30 ESTNewsModerna slips ahead of legal battle to invalidate COVID-19 vaccine patentsN/A
2021-09-22 20:29 ESTNewsArbutus Biopharma (ABUS) Investor Presentation - SlideshowN/A

About Arbutus Biopharma Corporation (ABUS):

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Quotes by TradingView

See Advanced Chart

General

  • Name Arbutus Biopharma Corporation
  • Symbol ABUS
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 76
  • Last Split Factor1:5
  • Last Split Date2010-11-04
  • Fiscal Year EndDecember
  • IPO Date2015-08-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.arbutusbio.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 40.69
  • Price/Book (Most Recent Quarter) 2.44
  • Enterprise Value Revenue 56.13
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.86
  • Next Year EPS Estimate -$0.67
  • Next Quarter EPS Estimate -$0.23
  • Operating Margin -828%
  • Return on Assets -30%
  • Return on Equity -73%
  • Revenue 6.91 million
  • Earnings Per Share -$1.79
  • Revenue Per Share $0.09
  • Gross Profit -40567000
  • Quarterly Earnings Growth 47.5%
View More

Highlights

  • Market Capitalization 349.26 million
  • EBITDA -71643000
  • PE Ratio -9.48
  • Analyst Target Price $6.11
  • Book Value Per Share $1.23
View More

Share Statistics

  • Shares Outstanding 95.58 million
  • Shares Float 69.81 million
  • % Held by Insiders 2123%
  • % Held by Institutions 30.96%
  • Shares Short 3.27 million
  • Shares Short Prior Month 2.55 million
  • Short Ratio 0.94
  • Short % of Float 5%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 3.05
  • 52 Week High $6.48
  • 52 Week Low $0.88
  • 50 Day Moving Average 3.96
  • 200 Day Moving Average 3.56
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Arbutus Biopharma Corporation (ABUS) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Arbutus Biopharma Corporation (ABUS) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-04$2.39 million-$0.23-$0.22-2.74%
2020-09-302020-11-05$N/A-$0.27-$0.22-26.07%
2020-06-302020-08-07$N/A-$0.25-$0.24-1.59%
2020-03-312020-05-11$1.49 million-$0.25-$0.3120.71%
2019-12-312020-03-05$1.62 million-$0.46-$0.36-26.6%
2019-09-302019-11-06$3.06 million-$1.50-$0.34-346.17%
2019-06-302019-08-05$653000-$0.46-$0.38-22.19%
2019-03-312019-05-06$679000-$0.47-$0.32-46.41%
2018-12-312019-03-07$1.68 million-$0.37-$0.406.98%
2018-09-302018-11-07$1.59 million-$0.49-$0.41-19.75%
2018-06-302018-08-02$1.24 million$0.01-$0.39102.54%
2018-03-312018-05-03$1.44 million-$0.36-$0.4010.76%
2017-12-312018-03-14$2.53 million-$0.67-$0.38-73.97%
2017-09-302017-11-02$6.89 million-$0.21-$0.3540.78%
2017-06-302017-08-03$1.04 million-$0.33-$0.4221.27%
2017-03-312017-05-04$235000-$0.34-$0.30-12.68%
2016-12-312017-03-21$-195000-$4.08-$0.40-932.74%
2016-09-302016-11-03$774000-$0.37-$0.5025.5%
2016-06-302016-08-04$309000-$2.47-$0.39-528.02%
2016-03-312016-05-04$603000-$0.31-$0.3716.46%
2015-12-312016-03-09$15.26 million-$0.10-$0.3974.17%
2015-09-302015-11-05$4.07 million-$0.12-$0.2958.62%
2015-06-302015-08-07$869000-$0.27-$0.296.9%
2015-03-312015-05-06$4.68 million-$0.40-$0.36-11.11%
2014-12-312015-03-12$4.35 million-$0.27-$0.283.57%
2014-09-302014-11-06$4.36 million-$0.39-$0.31-25.81%
2014-06-302014-08-13$1.81 million-$0.28-$0.25-12%
2014-03-312014-05-14$4.43 million-$0.91$0.16-668.75%
2013-12-312014-03-06$7.51 million-$0.10$0.06-266.67%
2013-09-302013-11-13$2.96 million-$0.42-$0.21-100%
2013-06-302013-08-12$2.79 million-$0.21
2013-03-312013-05-14$2.16 million-$0.18
2012-12-312013-03-27$3.91 million$2.70
2012-09-302012-11-13$3.1 million-$0.25
2012-06-302012-08-14$3.56 million-$0.14-$0.1612.5%
2012-03-312012-05-15$3.6 million-$0.25-$0.17-47.06%
2011-12-312012-03-27$3.66 million-$0.15
2011-09-302011-11-08$3.96 million-$0.12-$0.3060%
2011-06-302011-08-11$4.58 million-$0.33-$0.30-10%
2011-03-312011-05-10$4.48 million-$0.30-$0.3616.67%
2010-12-312011-03-30$6.21 million-$0.20-$0.2520%
2010-09-302010-11-15$4.34 million-$1.09-$0.20-445%
2010-06-302010-08-12$2.18 million-$0.40-$0.35-14.29%
2009-12-312010-03-17$4.27 million-$0.25-$0.3016.67%
2009-06-302009-08-12$3.25 million-$0.20-$0.15-33.33%
2009-03-312009-05-13$2.28 million-$0.20-$0.2520%
2008-12-312009-03-24$2.53 million-$0.35-$0.5030%
2007-12-312008-03-30$4.22 million$0.10$0.05100%
2007-09-302007-11-14$5.76 million$0.30$0.45-33.33%
2007-06-302007-08-08$2.82 million-$1.05-$0.30-250%

Arbutus Biopharma Corporation (ABUS) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Arbutus Biopharma Corporation (ABUS) Chart:

Arbutus Biopharma Corporation (ABUS) News:

Below you will find a list of latest news for Arbutus Biopharma Corporation (ABUS) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Arbutus Biopharma Corporation (ABUS) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-1710CALL0 0320.21TRUE00
2025-04-1720CALL0 0788.91TRUE00
2025-04-1730.08CALL1 2114.9TRUE-0.32-0.8
2025-04-1740.02CALL15 99546.13FALSE0.020
2025-04-1750.05CALL0 50100.35FALSE00
2025-04-1760CALL0 0137.13FALSE00
2025-04-1770CALL0 0190.24FALSE00
2025-04-1710PUT0 0776.25FALSE00
2025-04-1720PUT0 0399.95FALSE00
2025-04-1730.05PUT155 1772.8FALSE-0.05-0.5
2025-04-1740.76PUT0 3144.54TRUE00
2025-04-1750PUT0 0123.46TRUE00
2025-04-1760PUT0 0218.36TRUE00
2025-04-1770PUT0 00TRUE00
2025-05-1610CALL0 0305.45TRUE00
2025-05-1620CALL0 088.97TRUE00
2025-05-1630.6CALL2 556.71TRUE0.190.46
2025-05-1640.11CALL45 4553.37FALSE0.110
2025-05-1650CALL0 074.07FALSE00
2025-05-1660CALL0 0188.33FALSE00
2025-05-1610PUT0 0489.6FALSE00
2025-05-1620PUT0 0252.58FALSE00
2025-05-1630PUT0 054.29FALSE00
2025-05-1640PUT0 043.05TRUE00
2025-05-1650PUT0 071.07TRUE00
2025-05-1660PUT0 0126.3TRUE00
2025-06-2010CALL0 0213.85TRUE00
2025-06-2021.55CALL4 3980.45TRUE0.20.15
2025-06-2030.6CALL1 255261.71TRUE0.10.2
2025-06-2040.21CALL147 962056.42FALSE0.010.05
2025-06-2050.08CALL25 49363.88FALSE0.080
2025-06-2060.05CALL13 9475.16FALSE0.050
2025-06-2070.15CALL0 30161.87FALSE00
2025-06-2010PUT0 0373.44FALSE00
2025-06-2020PUT0 0192.94FALSE00
2025-06-2030.22PUT0 251752.57FALSE00
2025-06-2040.7PUT2 16560.12TRUE0.70
2025-06-2050PUT0 057.11TRUE00
2025-06-2060PUT0 086.13TRUE00
2025-06-2070PUT0 0117.41TRUE00
2025-08-150.50CALL0 0210.43TRUE00
2025-08-1510CALL0 0273.17TRUE00
2025-08-151.50CALL0 0380.64TRUE00
2025-08-1520CALL0 0334.83TRUE00
2025-08-152.51.15CALL0 9350.71TRUE00
2025-08-1530.7CALL0 11456.84TRUE00
2025-08-153.50.5CALL42 206755.36TRUE0.50
2025-08-1540.3CALL33 230253.49FALSE0.050.2
2025-08-154.50.11CALL0 7149.27FALSE00
2025-08-1550.2CALL0 53752.35FALSE00
2025-08-155.50CALL0 056.27FALSE00
2025-08-1560.18CALL0 1073.43FALSE00
2025-08-1570.3CALL0 281.55FALSE00
2025-08-150.50PUT0 0530.18FALSE00
2025-08-1510PUT0 0289.91FALSE00
2025-08-151.50PUT0 0203.67FALSE00
2025-08-1520PUT0 070.91FALSE00
2025-08-152.50.2PUT0 4654.56FALSE00
2025-08-1530.25PUT0 3445.31FALSE00
2025-08-153.50.5PUT60 220461.58TRUE0.50
2025-08-1541.08PUT0 154.14TRUE00
2025-08-154.50PUT0 082.1TRUE00
2025-08-1550PUT0 057.35TRUE00
2025-08-155.50PUT0 0106.19TRUE00
2025-08-1560PUT0 075.46TRUE00
2025-08-1570PUT0 094.74TRUE00
2025-09-1910CALL0 0166.67TRUE00
2025-09-1921.5CALL0 5207.29TRUE00
2025-09-1930.56CALL0 101259.44TRUE00
2025-09-1940.3CALL0 539.3FALSE00
2025-09-1950.05CALL0 2750.13FALSE00
2025-09-1960CALL0 051.16FALSE00
2025-09-1970CALL0 061.65FALSE00
2025-09-1910PUT0 0259.88FALSE00
2025-09-1920PUT0 063.72FALSE00
2025-09-1930.45PUT0 104040.96FALSE00
2025-09-1940.85PUT0 8054.57TRUE00
2025-09-1950PUT0 052.7TRUE00
2025-09-1960PUT0 00TRUE00
2025-09-1970PUT0 00TRUE00
2025-10-1710CALL0 0132.27TRUE00
2025-10-1721.4CALL0 479.44TRUE00
2025-10-1730CALL0 063.35TRUE00
2025-10-1740.48CALL100 4460.96FALSE0.080.2
2025-10-1750.18CALL0 558.32FALSE00
2025-10-1760.1CALL0 2660.4FALSE00
2025-10-1770CALL0 057.04FALSE00
2025-10-1780CALL0 065.06FALSE00
2025-10-1710PUT0 0241.69FALSE00
2025-10-1720PUT0 066.51FALSE00
2025-10-1730PUT0 044.56FALSE00
2025-10-1740.85PUT43 28556.09TRUE0.850
2025-10-1750PUT0 059.36TRUE00
2025-10-1760PUT0 00TRUE00
2025-10-1770PUT0 073.31TRUE00
2025-10-1780PUT0 092.4TRUE00
2026-01-160.50CALL0 00TRUE00
2026-01-1612.55CALL0 50TRUE00
2026-01-161.50CALL0 0176.89TRUE00
2026-01-1621.8CALL0 160197.91TRUE00
2026-01-162.51.35CALL0 66209.81TRUE00
2026-01-1631.15CALL0 18231.9TRUE00
2026-01-163.51CALL21 16477.99TRUE10
2026-01-1640.8CALL0 3443.15FALSE00
2026-01-164.51CALL0 61246.31FALSE00
2026-01-1650.6CALL0 126201.11FALSE00
2026-01-165.50.5CALL0 26246.6FALSE00
2026-01-1670CALL0 064.7FALSE00
2026-01-160.50PUT0 00FALSE00
2026-01-1610PUT0 00FALSE00
2026-01-161.50PUT0 077.89FALSE00
2026-01-1620PUT0 065.96FALSE00
2026-01-162.50PUT0 062.98FALSE00
2026-01-1630.3PUT0 455.24FALSE00
2026-01-163.50PUT0 042.55TRUE00
2026-01-1641.06PUT0 1531.64TRUE00
2026-01-164.51.46PUT0 10042.71TRUE00
2026-01-1650PUT0 081.82TRUE00
2026-01-165.50PUT0 066.45TRUE00
2026-01-1670PUT0 00TRUE00
2027-01-152.51.55CALL0 27137.86TRUE00
2027-01-1530CALL0 0209.24TRUE00
2027-01-153.51.26CALL7 250.51TRUE1.260
2027-01-1541.1CALL9 964.35FALSE1.10
2027-01-154.50CALL0 0167.25FALSE00
2027-01-1550.77CALL0 15171.81FALSE00
2027-01-155.50.71CALL1 18661.73FALSE0.010.01
2027-01-1570.5CALL1 9362FALSE0.50
2027-01-152.50PUT0 048.62FALSE00
2027-01-1530.81PUT0 141.24FALSE00
2027-01-153.51PUT0 135.67TRUE00
2027-01-1540PUT0 030.32TRUE00
2027-01-154.50PUT0 072.02TRUE00
2027-01-1550PUT0 076.28TRUE00
2027-01-155.50PUT0 085.12TRUE00
2027-01-1570PUT0 00TRUE00

Latest ABUS Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST400$2.39
Jun 13, 2022 7:59 PM EST200$2.39
Jun 13, 2022 7:59 PM EST1000$2.39
Jun 13, 2022 7:59 PM EST200$2.385
Jun 13, 2022 7:59 PM EST17$2.385

Arbutus Biopharma Corporation (ABUS) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2019-12-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1447028/000000000019016815/0000000000-19-016815-index.htm
2020-07-16SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000089542120000423/0000895421-20-000423-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000089924319019548/0000899243-19-019548-index.htm
2019-01-03SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000004/0000903423-19-000004-index.htm
2019-01-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000012/0000903423-19-000012-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000288/0000903423-19-000288-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000298/0000903423-19-000298-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000090342319000299/0000903423-19-000299-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583619000122/0000935836-19-000122-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000093583620000133/0000935836-20-000133-index.htm
2018-12-20424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000104746918007755/0001047469-18-007755-index.htm
2019-04-23DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746919002498/0001047469-19-002498-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1447028/000104746920002560/0001047469-20-002560-index.htm
2018-12-20S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074106/0001104659-18-074106-index.htm
2018-12-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465918074112/0001104659-18-074112-index.htm
2019-02-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919006779/0001104659-19-006779-index.htm
2019-02-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919008025/0001104659-19-008025-index.htm
2019-04-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919023074/0001104659-19-023074-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919030387/0001104659-19-030387-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040421/0001104659-19-040421-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040422/0001104659-19-040422-index.htm
2019-07-16SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040589/0001104659-19-040589-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040594/0001104659-19-040594-index.htm
2019-07-17SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040598/0001104659-19-040598-index.htm
2019-07-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919040934/0001104659-19-040934-index.htm
2019-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000110465919045102/0001104659-19-045102-index.htm
2019-11-05SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919059987/0001104659-19-059987-index.htm
2019-12-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465919070902/0001104659-19-070902-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000110465920020447/0001104659-20-020447-index.htm
2020-08-28S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000110465920100169/0001104659-20-100169-index.htm
2018-11-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001084/0001123292-18-001084-index.htm
2018-11-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001085/0001123292-18-001085-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm
2018-12-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001115/0001123292-18-001115-index.htm
2018-12-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329218001125/0001123292-18-001125-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000431/0001123292-19-000431-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000432/0001123292-19-000432-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000435/0001123292-19-000435-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000436/0001123292-19-000436-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000437/0001123292-19-000437-index.htm
2019-03-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000438/0001123292-19-000438-index.htm
2019-06-263Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000910/0001123292-19-000910-index.htm
2019-06-264Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000112329219000911/0001123292-19-000911-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034587/0001144204-19-034587-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000114420419034595/0001144204-19-034595-index.htm
2018-08-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006281/0001171843-18-006281-index.htm
2018-10-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318006907/0001171843-18-006907-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007089/0001171843-18-007089-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318007727/0001171843-18-007727-index.htm
2018-11-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184318008152/0001171843-18-008152-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319001586/0001171843-19-001586-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319002996/0001171843-19-002996-index.htm
2019-06-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004042/0001171843-19-004042-index.htm
2019-07-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319004412/0001171843-19-004412-index.htm
2019-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184319005142/0001171843-19-005142-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000117184320007636/0001171843-20-007636-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193243/0001193125-19-193243-index.htm
2019-07-12SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1447028/000119312519193262/0001193125-19-193262-index.htm
2019-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000120919119041996/0001209191-19-041996-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000006/0001447028-19-000006-index.htm
2019-03-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000010/0001447028-19-000010-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000015/0001447028-19-000015-index.htm
2019-05-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000018/0001447028-19-000018-index.htm
2019-08-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000025/0001447028-19-000025-index.htm
2019-08-09S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000031/0001447028-19-000031-index.htm
2019-08-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000049/0001447028-19-000049-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000050/0001447028-19-000050-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000051/0001447028-19-000051-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000052/0001447028-19-000052-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000053/0001447028-19-000053-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000054/0001447028-19-000054-index.htm
2019-08-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000055/0001447028-19-000055-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000056/0001447028-19-000056-index.htm
2019-08-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000057/0001447028-19-000057-index.htm
2019-08-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000060/0001447028-19-000060-index.htm
2019-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000064/0001447028-19-000064-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000069/0001447028-19-000069-index.htm
2019-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702819000071/0001447028-19-000071-index.htm
2019-12-23S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1447028/000144702819000078/0001447028-19-000078-index.htm
2019-12-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702819000081/0001447028-19-000081-index.htm
2020-01-08CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000004/0001447028-20-000004-index.htm
2020-01-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000006/0001447028-20-000006-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000009/0001447028-20-000009-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000024/0001447028-20-000024-index.htm
2020-02-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000025/0001447028-20-000025-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000026/0001447028-20-000026-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000027/0001447028-20-000027-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000028/0001447028-20-000028-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000029/0001447028-20-000029-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000030/0001447028-20-000030-index.htm
2020-02-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000031/0001447028-20-000031-index.htm
2020-03-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000035/0001447028-20-000035-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000038/0001447028-20-000038-index.htm
2020-03-0610-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000041/0001447028-20-000041-index.htm
2020-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000043/0001447028-20-000043-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000046/0001447028-20-000046-index.htm
2020-05-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000049/0001447028-20-000049-index.htm
2020-05-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000052/0001447028-20-000052-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000063/0001447028-20-000063-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000064/0001447028-20-000064-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000065/0001447028-20-000065-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000066/0001447028-20-000066-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000067/0001447028-20-000067-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000068/0001447028-20-000068-index.htm
2020-06-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000069/0001447028-20-000069-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000071/0001447028-20-000071-index.htm
2020-06-24S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000073/0001447028-20-000073-index.htm
2020-07-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000078/0001447028-20-000078-index.htm
2020-07-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000100/0001447028-20-000100-index.htm
2020-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000118/0001447028-20-000118-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000121/0001447028-20-000121-index.htm
2020-08-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000124/0001447028-20-000124-index.htm
2020-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000126/0001447028-20-000126-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000129/0001447028-20-000129-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000135/0001447028-20-000135-index.htm
2020-09-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000140/0001447028-20-000140-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000143/0001447028-20-000143-index.htm
2020-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000144702820000144/0001447028-20-000144-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000144702820000150/0001447028-20-000150-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315219001945/0001493152-19-001945-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1447028/000149315220002406/0001493152-20-002406-index.htm
2018-08-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-08-154/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918001171/0001567619-18-001171-index.htm
2018-10-103Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003916/0001567619-18-003916-index.htm
2018-10-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918003919/0001567619-18-003919-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004374/0001567619-18-004374-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004376/0001567619-18-004376-index.htm
2018-10-223Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004378/0001567619-18-004378-index.htm
2018-10-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1447028/000156761918004380/0001567619-18-004380-index.htm
2018-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1447028/000162828018013909/0001628280-18-013909-index.htm
2020-01-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520000069/9999999995-20-000069-index.htm
2020-10-22EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1447028/999999999520002943/9999999995-20-002943-index.htm
2020-07-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004141/9999999997-20-004141-index.htm
2020-09-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1447028/999999999720004563/9999999997-20-004563-index.htm

Arbutus Biopharma Corporation (ABUS) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Arbutus Biopharma Corporation (ABUS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 2123%
Institutional Ownership: 3096%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2020-07-23Michael J. McElhaughChief Business OfficerSell20,000.005.01100,200.001,367,457.00https://www.sec.gov/Archives/edgar/data/1447028/000144702820000080/0001447028-20-000080-index.htm
2018-08-13Michael J. SofiaChief Scientific OfficerSell4,250.009.5140,435.781,499,153.00https://www.sec.gov/Archives/edgar/data/1447028/000156761918001148/0001567619-18-001148-index.htm
2018-11-28Mark J. MurrayDirectorBuy25,000.001.3533,750.00341,396.00https://www.sec.gov/Archives/edgar/data/1447028/000112329218001091/0001123292-18-001091-index.htm